Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

Blood Cancer J. 2017 Jul 14;7(7):e583. doi: 10.1038/bcj.2017.62.

Authors

Z Gong¹, L J Medeiros¹, J E Cortes², L Zheng¹, J D Khoury¹, W Wang¹, G Tang¹, S Loghavi¹, R Luthra¹, W Yang³, H M Kantarjian², S Hu¹

Affiliations

¹ Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aftercare
Aged
Aged, 80 and over
Disease-Free Survival
Female
Fusion Proteins, bcr-abl / biosynthesis*
Fusion Proteins, bcr-abl / genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality*
Male
Middle Aged
Survival Rate

Substances

BCR-ABL1 fusion protein, human
Fusion Proteins, bcr-abl